Mirati Therapeutics

MRTXNASDAQAcquired

Targeted oncology small-molecule development platform

Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-04-09. Published by Blane Jackson, DDS, MBA. Educational analysis only. Read the editorial policy and disclosures.

text updated 2026-04-09, 177 days ago · archived: kept for reference, not maintained · where each field comes from

oncologyprecision medicine

Pipeline at the time of the last update

DrugIndicationPhaseExpected data
KrazatiKRAS G12C-mutated non-small cell lung cancerApprovedNot disclosed▼
Adagrasib plus combinationsbroader KRAS G12C solid tumorsPhase 3Not disclosed▼
MRTX1719MTAP-deleted solid tumorsPhase 1Not disclosed▼

Comparable companies

BridgeBio PharmaBlueprint MedicinesRevolution Medicines
Disclaimer: This page is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Clinical trial analysis reflects publicly available data and AI-generated interpretations. Biotech investing carries significant risk including potential total loss of investment. Always verify critical claims through primary sources and consult a qualified financial advisor. Some links on this page are affiliate links. Review our editorial policy and disclosures.

Sponsor's late-stage trial record

Mirati Therapeutics has 25 Phase 2 or 3 studies on ClinicalTrials.gov: 10 completed, 7 stopped early, 8 ongoing.

10

Completed

7

Stopped early

8

Ongoing

Stopped early

  • NCT03606174Phase 2 · started 2018 · terminated

    Sitravatinib in urothelial carcinoma · n=260

    Reason given: The study was terminated due to sponsor decision / portfolio prioritization, and not due to safety reasons.

  • NCT02954991Phase 2 · started 2016 · terminated

    Glesatinib in carcinoma, non-small-cell lung · n=161

    Reason given: This study was terminated as a result of Sponsor portfolio reprioritization.

  • NCT02805660Phase 1/2 · started 2016 · terminated

    Mocetinostat - 50 mg in advanced cancer · n=83

    Reason given: The study was discontinued early because the Sponsor de-prioritized development of mocetinostat. The decision to stop was not due to any patient safety issues.

  • NCT00666497Phase 2 · started 2008 · terminated

    Azacitidine in acute myeloid leukemia (aml) · n=6

    Reason given: Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103. All Celgene-sponsored trials with MGCD0103 with be closed.

  • NCT00543582Phase 2 · started 2007 · terminated

    MGCD0103 and Azacitidine in hodgkin lymphoma · n=23

    Reason given: Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103. All Celgene-sponsored trials with MGCD0103 will be closed.

  • NCT00374296Phase 2 · started 2006 · terminated

    MGCD0103 in myelogenous leukemia, acute · n=35

    Reason given: The Clinical Development Program for MGCD0103 is being re-evaluated

  • NCT00358982Phase 2 · started 2006 · terminated

    MGCD0103 in hodgkin's lymphoma · n=51

    No reason recorded in the registry.

Counts cover interventional Phase 2 and Phase 3 studies registered under this sponsor name, retrieved 2026-09-28 from ClinicalTrials.gov API v2. Trials stop for many reasons — futility, safety, enrollment, funding, or a decision to back a different programme — and the registry often does not say which. This is the sponsor's record, not a prediction about any specific readout.